



# **Università degli Studi di Catania**

**Dottorato di ricerca –XXV CICLO**

**Patologia ed Ematologia Clinica, Sperimentale e Computazionale**

**Dott. MAIDE MARIA CAVALLI**

**PREDICTING SURVIVAL OUTCOMES IN MYELOMA USING**

**SURROGATE MARKERS**

**TESI DI DOTTORATO**

Relatore:

Chiar.mo Prof.F.Di Raimondo

## **ACKNOWLEDGMENTS**

*I would like to thank to my mentor prof. Francesco Di Raimondo for supporting me during these three past three years. He gave me great advices and great support.*

*I would like to thank to prof. S.Vincent Rajkumar and prof. Shaji Kumar. Their ideas had a major influence on this thesis. They spent a lot of time helping me. I learned a lot during six months that I spent at Mayo Clinic in Rochester, USA. This knowledge will help me in the future.*

*I'm lucky because I met three outstanding working examples.*

INTRODUCTION.....	4
DESIGN AND METHOD .....	5
Data sources and search .....	5
Statistical analysis .....	6
RESULTS .....	6
Literature search results .....	6
Magnitude of PFS benefit required for survival improvement.....	7
Magnitude of complete response benefit required for survival improvement .....	8
PFS benefit in clinical studies with no significant improvement in OS .....	8
CR benefit in clinical studies with no significant improvement in OS.....	10
DISCUSSION.....	13
BIBLIOGRAPHY .....	17

## INTRODUCTION

During the last ten years, the number of randomized controlled trials (RCTs) evaluating various treatment strategies in Multiple Myeloma (MM) has increased. Studies are being conducted worldwide, including an increasing number of multicenter, international trials.<sup>1</sup> As the number of treatment options has increased over time, there has been considerable debate as to the most relevant endpoints in this disease. The International Myeloma Workshop Consensus Panel considers progression free survival (PFS) and overall survival (OS) as essential endpoints for efficacy in phase III trials.<sup>2</sup> In regulatory clinical trials, endpoint as PFS is meaningful in a disease, such as MM, because a significant prolongation of this endpoint can be reasonably indicative of clinical benefit.<sup>1,3-5</sup> PFS is an indicator of drug activity<sup>6</sup> and it is an appropriate endpoint for the approval of new drug in MM to avoid delays in getting new drugs into practice. However, OS should be considered the gold standard before adopting a particular treatment strategy as standard of care. Given the considerable improvement in overall survival (OS) seen in MM during the past decade, and the limited number of patients that can be enrolled into phase III trials, use of OS as trial endpoint results in long trial duration. However, given the long duration of follow up required of such trials we need to identify reliable predictors of improved OS early on. These early surrogate markers are not for early adoption of potential trial results, but to guide us in the design subsequent trial strategies ahead of time.

We designed this study to evaluate if there is a minimum improvement on PFS that will translate into an OS benefit in a reasonably high proportion of trials, or if there is a threshold of PFS improvement below which an OS benefit is unlikely to happen. Prolongation of OS in MM is

almost always associated with prolonged PFS, but not the other way around<sup>7-9</sup>. Identification of such thresholds will allow us to make reasonable hypothesis for future trials designs without having to wait for a long period for the mature results from existing clinical trials. The primary objective of our project was to investigate whether there was a required minimum PFS difference between two arms in phase III randomized controlled trials (RCTs) that can be used as a predictor of benefit in overall survival (OS). Secondary objectives were to explore if there was a minimum threshold for VGPR rate and CR rate difference between two arms that will predict PFS difference or OS difference in RCTs.

## **DESIGN AND METHOD**

### **Data sources and search**

We performed a PUBMED search to identify potentially relevant randomized controlled trials (RCTs) using the terms “Multiple myeloma”, “Randomized clinical trial”, “phase III/3”, published between January 1992 to January 2012. We also scanned references of abstracts presented at the American Society of Hematology (ASH) using the same terms between January 2005 to August 2012; this was supplemented by manual searches of others clinical trials. We included only the RCTs that reported CR, VGPR, progression-free survival or event-free survival (PFS/EFS), time to progression (TTP), overall survival (OS) on intention-to- treat basis. We also examined the relationships within different subgroups such frontline, relapse or refractory, stem-cell transplantation (SCT), maintenance trials, chemotherapy (CHT) and SCT, old and new drug trials.

## **Statistical analysis**

We used both absolute differences in the survival improvement (in months) and response rates between the two arms, as well as proportional improvements for the purpose of analysis.

Descriptive statistics were used to summarize the minimum threshold PFS, CR AND VGPR median differences respectively. All analyses were performed using JMP Software Version 9.0.1.

## **RESULTS**

### **Literature search results**

The initial literature search identified 314 papers for review; 17 other papers were identified by manual research. Assessment of these publications resulted in identification of 75 RCTs. All 75 RCTs were in PHASE III and presented an adequate randomization procedure.<sup>3-5,7,10-82</sup> Of the 75 RCTs studied, 17 (22%) had statistically significant improvement in OS on intent to treat analysis ( $p\text{-value} \leq 0.05$ )<sup>3,5,18,30,34,36,37,39,40,46-48,50,65,68,74,79,81</sup>. Data to estimate median improvement in PFS was present in all of these trials. One of these trials (Facon et al<sup>48</sup>) had three arms, in which the arm with significant OS advantage was significantly better than each of the two other arms, and was therefore considered for purposes of this analysis as two trials. Thus 18 trials were included to estimate the magnitude of PFS benefit that resulted in a significant OS advantage (Table 1).

## Magnitude of PFS benefit required for survival improvement

We found that the minimum improvement in median PFS/TTP required to produce a significant improvement in OS was at least 2.5 months or more<sup>34,39,46 3,5,18,30,36,37,40,47,48,50,65,68,74,79,81</sup>. We observed that this number varied depending on the stage of the disease and the type of treatment. Of the 18 trials, 11 were frontline (61%)<sup>30,34,36,40,46,48,68,74,79,83</sup>, 4 were relapsed (22%)<sup>3-5,84</sup>, 1 was consolidation (6%)<sup>50,81</sup> and 2 was maintenance (11%)<sup>18,39</sup>. In frontline trials, all 11 trials had a PFS benefit of at least 4 months or more (range, 4-12.4 months). In fact, in 73% of frontline trials, the minimum improvement in PFS required to observe a significant improvement in OS was 7 months or more. In all 4 relapse or refractory trials the PFS benefit associated with significant OS improvement was 2.5 months or more. In the 1 consolidation trial that had a significant OS benefit, the PFS improvement was 6 months. In the 2 maintenance trials, the PFS improvement was 12.2 months or more.

We then assessed the magnitude of PFS benefit required for OS improvement based on treatment modality. In the 14 chemotherapy trials the PFS benefit needed for OS improvement was at least 2.5 months<sup>3,5,18,30,34,36,37,39,40,46-48,68,79</sup> while in the 4 SCT trials, the minimum PFS benefit was 6 months or more<sup>48,50,65,74,81</sup>. In 13 trials that used new agents (thalidomide, lenalidomide, or bortezomib), the minimum improvement in median PFS required for an OS benefit was 2.5 months<sup>3,5,18,30,36,37,39,40,46-48</sup>; the corresponding value for the 5 trials using older agents was 5 months<sup>50,65,81 68,74,79</sup>

## **Magnitude of complete response benefit required for survival improvement**

The improvement in CR required for survival improvement could be calculated in 16<sup>3-5,18,34,36,39,40,46,48,50,68,74,79,81,84</sup> of the 18 trials in which CR rates were reported . In newly diagnosed myeloma (9 trials)<sup>34,36,40,46,48,68,74,79</sup> , CR improvements appeared to be widely variable, ranging from -5% (arm with survival improvement having worse CR rate by -5%) to 36%, with no particular pattern relative to type of therapy administered and the minimum threshold needed for survival benefit. In 2 trials, CR was either not improved or was worse in the arm with superior survival. In 4 trials (50%) the improvement in CR was less than 10%, while in 2 trials an absolute increase in CR rates of over 25% was seen.

We tried to determine the minimum increase in VGPR that is associated with improved OS, but VGPR rates were reported only in 5<sup>34,39,40,46,74</sup> of the 18 trials , and therefore could not be accurately computed.

## **PFS benefit in clinical studies with no significant improvement in OS**

Of 75 RCTs, 58 (77%) hadn't statistically significant improvement in OS<sup>7,11-17,19-29,31-33,35,38,41-45,48,49,51-54,56-64,66,67,69-73,75-78,82,85-87</sup> . 5 of 58 clinical trials with more than two arms<sup>14,17,44,52,86</sup> were considered as different trials with comparison of each pair of arms being a different two-arm trial.

The PFS improvement could be calculated in 48 of 65 RCTs with no significant benefit in OS. Of 48 trials, 27 (56%)<sup>7,12,14,16,17,21,24,31,33,35,41,42,45,52,54,59,60,62,64,67,76,85,88</sup> were newly diagnosed, 13 (27%)<sup>15,19,23,38,44,49,56,69,77,86</sup> were in relapse, 2 (4%)<sup>43,82</sup> were in consolidation and 7 (14%)<sup>13,28,32,63,70,71,75</sup> were in maintenance . In these trials the minimum PFS improvement was

0.37, 0.1, 26 and 5.1 months respectively. Sixteen of 49 RCTs (33%) with no OS improvement had a PFS improvement less than the minimum threshold of 2.5 months that we had identified as being required for OS benefit.

Of the 27 newly diagnosed myeloma trials, 10 (37%) had PFS improvement less than the minimum threshold of 4 months that we had identified as being required for OS benefit. Among all newly diagnosed myeloma trials (11 with survival improvement and 27 without), a PFS improvement of less than 4 months was never associated with survival benefit, while an improvement of 4 months or more was associated with a 39% probability of a significant OS benefit (11 of 28 trials).

Similarly of 13 relapsed MM trials, 9 (69%) had PFS improvement less than the minimum threshold of 2.5 months that we had identified as being required for OS benefit. Among all relapsed myeloma trials (4 with survival improvement and 13 without), a PFS improvement of less than 2.5 months was never associated with survival benefit, while an improvement of 2.5 months or more was associated with a 50% probability of a significant OS benefit (4 of 8 trials).

All 2 consolidation trials had PFS improvement more than the minimum threshold of 6 months. Among all consolidation myeloma trials (1 with survival improvement and 2 without), a PFS improvement of less than 6 months was never associated with survival benefit, while an improvement of 6 months or more was associated with a 33% probability of a significant OS benefit (1 of 3 trials).

On 7 maintenance trials, 2 (29%) had PFS improvement less than the minimum threshold of 12.2 months. Among all maintenance trials (2 with survival improvement and 2 without), a PFS improvement of less than 12.2 months was never associated with survival

benefit, while an improvement of 12.2 months or more was associated with a 50% probability of a significant OS benefit (2 of 4 trials).

Of the 43 chemotherapy and of 6 transplant myeloma trials, 15 (35%) and 2 (33%) had PFS improvement less than the minimum threshold of 2.5 and 6 months that we had identified as being required for OS benefit. Among all chemotherapy and transplant myeloma trials (12 and 4 with survival improvement and 43 and 6 without), a PFS improvement of less than 2.5 and 6 months was never associated with survival benefit, while an improvement of 2.5 and 6 months or more was associated with a 30% and 50% probability of a significant OS benefit (12 and 4 of 40 and 8 trials), respectively.

Of the 30 new and of 19 old myeloma trials, 12 (40%) and 7 (37%) had PFS improvement less than the minimum threshold of 2.5 and 5 months that we had identified as being required for OS benefit. Among all new and old drug myeloma trials, respectively, (11 and 5 with survival improvement and 18 and 11 without), a PFS improvement of less than 2.5 and 5 months was never associated with survival benefit, while an improvement of 2.5 and 5 months or more was associated with a 38% and 31% probability of a significant OS benefit (11 and 5 of 29 and 16 trials), respectively.

### **CR benefit in clinical studies with no significant improvement in OS**

Of 75 RCTs, 48 (64%) did not show a statistically significant improvement in OS.

Of 48 trials, 31 (65%) were newly diagnosed, 9 (19%) were relapsed patients, 4 (8%) on consolidation therapy and remaining 4 (8%) analyzed maintenance therapy (Table). In these

trials the minimum CR improvement was 19, 5, 3 and 3 months respectively. Sixteen of 49 RCTs (33%) with no OS improvement had a PFS improvement less than the minimum threshold of 2.5 months that we had identified as a requirement for achieving a statistically significant OS benefit.

Of the 31 newly diagnosed myeloma trials, 12 (39%) had CR improvement less than the minimum threshold of 3.2 months that we had identified as being required for OS benefit.

Among all newly diagnosed myeloma trials (7 with survival improvement and 31 without), a CR improvement less than 3.2 months was never associated with a survival benefit, while an improvement of 3.2 months or more was associated with a 27% probability of a significant OS benefit (7 of 26 trials).

Similarly of 9 relapsed MM trials, 5 (56%) had PFS improvement less than the minimum threshold of 2 months that we identified to be a requirement for attaining an OS benefit.

Among all relapsed myeloma trials (4 with survival improvement and 5 without), a CR improvement of less than 2 months did not correlate with a survival benefit, while an improvement of 2 months or more was associated with a 44% probability of a significant OS benefit (4 of 9 trials).

All 4 consolidation trials had CR improvement more than the minimum threshold of 10 months. Among these trials (2 with survival improvement and 3 without), a CR improvement of less than 10 months did not associate with a corresponding survival benefit, while an improvement of 10 months or more was associated with a 40% probability of a significant OS benefit (2 of 5 trials).

On 4 maintenance trials, 1 (25%) had CR improvement less than the minimum threshold of 2 months. These trials (2 with survival improvement and 3 without) showing a CR improvement of less than 2 months was unassociated with survival benefit, while an improvement of 2 months or more showed an association with a 40% probability of a significant OS benefit (2 of 5 trials).

Of the 42 chemotherapy and of 6 transplant myeloma trials, 12 (29%) and 2 (33%) had CR improvement less than the minimum threshold of 2 and 5 months that we identified as a requirement to obtain an OS benefit. Amongst all chemotherapy and transplant myeloma trials (11 and 4 with survival improvement; 30 and 4 without), a CR improvement of less than 2 and 5 months was not associated with survival benefit, while an improvement of 2 and 5 months or more was associated with a 27% and 50% probability of a significant OS benefit (11 of 41 and 4 of 8 trials), respectively.

Of the 28 new and 20 old myeloma trials, 7(25%) and 14 (70%) had CR improvement less than the minimum threshold of 2 and 10 months respectively that we had identified to correlate with a significant OS benefit. Among all new and old drug myeloma trials (11 and 4 with survival improvement; 21 and 6 without), a CR improvement not reaching 2 and 10 months respectively was not associated with a survival benefit, while vice versa showed a correlation with a 34% and 40% probability of a significant OS benefit (11 of 32 and 4 of 10 trials), respectively.

## DISCUSSION

Although RCTs are powerful instruments that help in defining the optimal method of interpreting the meaningful impact the treatment has on patients, they require prolonged follow up, need a large set of eligible patients and sometimes present with difficulties during randomization or recruitment along with significant costs.

Endpoints such as PFS and OS are the principal indicators to assess efficacy of therapies employed in clinical studies.

While Overall survival is the mainstay of measuring the full impact of the response to treatment, it requires a long follow-up period (over 5 years) before any inference could be drawn from initial response. PFS/TTP may or may not translate into overall survival benefit<sup>89</sup>; it may need a large sample size before significant results are achieved.

PFS is the recommended method to present trial results and it is considered an excellent surrogate marker for overall survival duration<sup>89,90</sup>. Hence in recent years the use of PFS has increased in all phase III RCTs.

In Oncology there has been an ongoing debate over the importance of a statistically significant improvement in PFS in the absence of a proven favorable impact on overall survival. We performed this study to investigate a minimum value of PFS improvement (the difference between ARM A and ARM B) which could possibly translate into OS benefit and hence provide a methodical guideline which could be used during the future development of Multiple Myeloma phase III RCTs.

We analyzed of 18 randomized phase III trials that reported an OS benefit. This helped us to identify a minimum PFS of 2.5 months as the minimum threshold value needed to achieve

a statistically significant benefit in OS. This was confirmed by further analyzing sixteen of 49 (33%) RCTs where no OS benefit was attained where the PFS was reported less than 2.5 months.

This minimum value of PFS varies with disease phase and the type of therapy used. In both, the frontline and relapsed RCT's that showed an OS improvement, the minimum threshold value of PFS benefit was 4 months and 2.5 months respectively while in 37% and 69% newly diagnosed and relapsed trials without an improved OS the reported PFS benefit was less than 4 and 2.5 months, respectively. This improvement of 4 and 2.5 months or more was associated with a 39% and 50% probability of a significant OS benefit in all newly diagnosed and relapsed trials (significant and non-significant with a PFS improvement over 4 months). Those trial with no significant OS benefit but showing a minimum PFS improvement of 4 and 2.5 months, respectively, could report an improvement in OS benefit by increase their study power with an longer follow up or an increase in the number of patients enrolled.

Amongst OS significant trials we found 1 consolidation trial where the minimum PFS improvement was 6 months; 2 other consolidation trials with no OS significant reported a minimum PFS benefit more than 6 months with a 33%probability of a significant OS benefit in all consolidation trials (significant and non-significant with a PFS improvement over 6 months).

In 2 maintenance trials, the minimum PFS benefit needed to achieve a significant OS improvement was 12.2 months. In 29% of non- significant OS, maintenance trials a minimum PFS improvement under 12.2 months was never associated with survival benefit, but we observed an high probability (50%) of a significant OS benefit among all maintenance trials, with or without significant OS but with minimum PFS improvement more than 12.2 months.

In chemotherapy and in transplant RCTs that showed an OS improvement, the minimum value of PFS benefit was 2.5 and 6 months respectively while 15% and 2% of chemotherapy and transplant trials without survival improvement reported a PFS benefit under 2.5 and 6 months, respectively. An improvement of 2.5 and 6 months or more was associated with 30% and 50% probability of a significant OS benefit respectively in all chemotherapy and transplant trials.

Finally, our analysis about new and old drug trials showed a minimum PFS benefit of 2.5 and 5 months respectively. 40% novel and 37% old drug trials without a survival benefit reportedly achieved a PFS less than 2.5 and 5 months respectively. An improvement of 2.5 and 5 months or more was associated with 38% and 31% probability of a significant OS benefit in all the new and old drug trials respectively.

It will be useful for future trials to regularly interpret the PFS benefit seen.

We also calculated the minimum CR improvement to achieve a statistically significant benefit in OS, but the data presented wide variability ranging from -5% to 36% making it unsuitable for our purpose. There were also no particular pattern relating the type of therapy administered and the minimum threshold needed for survival benefit.

Lack of adequate data on the VGPR achieved in various trials hindered the analysis of VGPR for our project.

In conclusion, the challenges encountered during prolonged follow up before OS benefits can be interpreted, along with the treatment associated burgeoning costs could be efficiently managed by keeping the threshold PFS value in consideration, which could be a pivotal surrogate marker for predicting the trends in OS. But the current data is still immature

for such an interpretation and underpowered trials make the analysis of OS further challenging.

We are limited by lack of data on Multiple Myeloma clinical trials showing OS significance.

## BIBLIOGRAPHY

1. Richardson PG, Sonneveld P, Schuster MW, et al: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. *The New England journal of medicine* 352:2487-98, 2005
2. Rajkumar SV, Harousseau JL, Durie B, et al: Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. *Blood* 117:4691-5, 2011
3. Weber DM, Chen C, Niesvizky R, et al: Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. *N Engl J Med* 357:2133-42, 2007
4. Dimopoulos M, Spencer A, Attal M, et al: Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. *N Engl J Med* 357:2123-32, 2007
5. Orłowski RZ, Nagler A, Sonneveld P, et al: Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. *J Clin Oncol* 25:3892-901, 2007
6. Anderson KC, Kyle RA, Rajkumar SV, et al: Clinically relevant end points and new drug approvals for myeloma. *Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K* 22:231-9, 2008
7. Harousseau JL, Attal M, Avet-Loiseau H, et al: Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. *J Clin Oncol* 28:4621-9, 2010
8. Cavo M, Tacchetti P, Patriarca F, et al: Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. *Lancet* 376:2075-85, 2010
9. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 16:3832-42, 1998
10. Morgan GJ, Gregory WM, Davies FE, et al: The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. *Blood* 119:7-15, 2012
11. Cavo M, Pantani L, Petrucci MT, et al: Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. *Blood* 120:9-19, 2012
12. Morgan GJ, Davies FE, Gregory WM, et al: Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. *Haematologica* 97:442-50, 2012
13. Attal M, Lauwers-Cances V, Marit G, et al: Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. *N Engl J Med* 366:1782-91, 2012
14. Palumbo A, Hajek R, Delforge M, et al: Continuous lenalidomide treatment for newly diagnosed multiple myeloma. *N Engl J Med* 366:1759-69, 2012
15. Garderet L, Iacobelli S, Moreau P, et al: Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *J Clin Oncol* 30:2475-82, 2012

16. Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al: Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial. *J Clin Oncol* 30:2946-55, 2012
17. Rosiñol L, Oriol A, Teruel AI, et al: Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. *Blood* 120:1589-1596, 2012
18. McCarthy PL, Owzar K, Hofmeister CC, et al: Lenalidomide after stem-cell transplantation for multiple myeloma. *N Engl J Med* 366:1770-81, 2012
19. Hjorth M, Hjertner O, Knudsen LM, et al: Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. *European journal of haematology* 88:485-96, 2012
20. Palumbo A, Adam Z, Kropff M, et al: A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts)  $\geq$  65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM): Updated Results for Pts Aged 65-75 Yrs Enrolled in MM-015. *ASH Annual Meeting Abstracts* 118:475, 2011
21. Morgan GJ, Davies FE, Gregory WM, et al: Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. *Blood* 118:1231-1238, 2011
22. Bjorkstrand B, Iacobelli S, Hegenbart U, et al: Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 29:3016-22, 2011
23. Moreau P, Pylypenko H, Grosicki S, et al: Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. *Lancet Oncol* 12:431-40, 2011
24. Moreau P, Avet-Loiseau H, Facon T, et al: Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. *Blood* 118:5752-5758, 2011
25. Chou T, Tobinai K, Uike N, et al: Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112. *Jpn J Clin Oncol* 41:586-9, 2011
26. Beksac M, Haznedar R, Firatli-Tuglular T, et al: Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. *European journal of haematology* 86:16-22, 2011
27. Palumbo A, Bringhen S, Rossi D, et al: Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. *J Clin Oncol* 28:5101-9, 2010
28. Lokhorst HM, van der Holt B, Zweegman S, et al: A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. *Blood* 115:1113-1120, 2010
29. Zonder JA, Crowley J, Hussein MA, et al: Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). *Blood* 116:5838-5841, 2010

30. Wijermans P, Schaafsma M, Termorshuizen F, et al: Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. *J Clin Oncol* 28:3160-6, 2010
31. Waage A, Gimsing P, Fayers P, et al: Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. *Blood* 116:1405-1412, 2010
32. Stewart AK, Trudel S, Bahlis NJ, et al: A Randomized Phase III Trial of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT) In Patients with Multiple Myeloma (MM): The NCIC CTG MY.10 Trial. *ASH Annual Meeting Abstracts* 116:39, 2010
33. Rajkumar SV, Jacobus S, Callander NS, et al: Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. *The lancet oncology* 11:29-37, 2010
34. Ludwig H, Hajek R, Tóthová E, et al: Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. *Blood* 113:3435-3442, 2009
35. Kyle RA, Jacobus S, Friedenberg WR, et al: The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology Group Study E5A93. *Cancer* 115:2155-64, 2009
36. Hulin C, Facon T, Rodon P, et al: Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. *J Clin Oncol* 27:3664-70, 2009
37. Dimopoulos MA, Chen C, Spencer A, et al: Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. *Leukemia* 23:2147-52, 2009
38. Chanan-Khan AA, Niesvizky R, Hohl RJ, et al: Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. *Leuk Lymphoma* 50:559-65, 2009
39. Spencer A, Prince HM, Roberts AW, et al: Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 27:1788-93, 2009
40. San Miguel JF, Schlag R, Khuageva NK, et al: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. *N Engl J Med* 359:906-17, 2008
41. Rajkumar SV, Rosinol L, Hussein M, et al: Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. *J Clin Oncol* 26:2171-7, 2008
42. Palumbo A, Bringhen S, Liberati AM, et al: Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. *Blood* 112:3107-3114, 2008
43. Zangari M, van Rhee F, Anaissie E, et al: Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1. *Br J Haematol* 141:433-44, 2008
44. Sonneveld P, Hajek R, Nagler A, et al: Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. *Cancer* 112:1529-37, 2008
45. Sonneveld P, van der Holt B, Segeren CM, et al: Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial. *Haematologica* 92:928-35, 2007

46. Zervas K, Mihou D, Katodritou E, et al: VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group. *Ann Oncol* 18:1369-75, 2007
47. Richardson PG, Sonneveld P, Schuster MW, et al: Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. *Br J Haematol* 137:429-35, 2007
48. Facon T, Mary JY, Hulin C, et al: Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. *Lancet* 370:1209-18, 2007
49. Ning YM, He K, Dagher R, et al: Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma. *Oncology (Williston Park)* 21:1503-8; discussion 1511, 1513, 1516 passim, 2007
50. Bruno B, Rotta M, Patriarca F, et al: A comparison of allografting with autografting for newly diagnosed myeloma. *The New England journal of medicine* 356:1110-20, 2007
51. Rifkin RM, Gregory SA, Mohrbacher A, et al: Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial. *Cancer* 106:848-58, 2006
52. Facon T, Mary J-Y, Pégourie B, et al: Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. *Blood* 107:1292-1298, 2006
53. Barlogie B, Kyle RA, Anderson KC, et al: Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. *J Clin Oncol* 24:929-36, 2006
54. Moreau P, Hulin C, Garban F, et al: Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. *Blood* 107:397-403, 2006
55. Garban F, Attal M, Michallet M, et al: Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. *Blood* 107:3474-80, 2006
56. Friedenberg WR, Rue M, Blood EA, et al: Phase III study of PSC-833 (valsopodar) in combination with vincristine, doxorubicin, and dexamethasone (valsopodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. *Cancer* 106:830-8, 2006
57. Macro M DM, Uzunhan Y, et al: Dexamethasone+Thalidomide (Dex/Thal) Compared to VAD as a Pre-Transplant Treatment in Newly Diagnosed Multiple Myeloma (MM): A Randomized Trial American Society of Hematology, 2006, pp 57
58. Tricot G, Rasmussen E, Anaissie E, et al: Total Therapy 2 (TT2) for Multiple Myeloma (MM): Thalidomide (T) Effects Superior Complete Response (CR) and Event-Free Survival (EFS); Similar Overall Survival (OS) Linked to Shorter Post-Relapse Survival. *ASH Annual Meeting Abstracts* 106:423, 2005
59. Ludwig H, Spicka I, Klener P, et al: Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma. *Br J Haematol* 131:329-37, 2005
60. Femand JP, Katsahian S, Divine M, et al: High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 23:9227-33, 2005

61. Cavo M, Zamagni E, Tosi P, et al: Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. *Blood* 106:35-39, 2005
62. Bladé J, Rosiñol L, Sureda A, et al: High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. *Blood* 106:3755-3759, 2005
63. Schaar CG, Kluin-Nelemans HC, Te Marvelde C, et al: Interferon-alpha as maintenance therapy in patients with multiple myeloma. *Ann Oncol* 16:634-9, 2005
64. Takenaka T, Itoh K, Suzuki T, et al: Phase III study of ranimustine, cyclophosphamide, vincristine, melphalan, and prednisolone (MCNU-COP/MP) versus modified COP/MP in multiple myeloma: a Japan clinical oncology group study, JCOG 9301. *Int J Hematol* 79:165-73, 2004
65. Palumbo A, Bringhen S, Bertola A, et al: Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m<sup>2</sup>). *Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K* 18:133-8, 2004
66. Cook G, Clark RE, Morris TC, et al: A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma. *Br J Haematol* 126:792-8, 2004
67. Dimopoulos MA, Pouli A, Zervas K, et al: Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. *Ann Oncol* 14:1039-44, 2003
68. Child JA, Morgan GJ, Davies FE, et al: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. *N Engl J Med* 348:1875-83, 2003
69. Sonneveld P, Suci S, Weijermans P, et al: Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). *Br J Haematol* 115:895-902, 2001
70. Offidani M, Olivieri A, Montillo M, et al: Two dosage interferon-alpha 2b maintenance therapy in patients affected by low-risk multiple myeloma in plateau phase: a randomized trial. *Haematologica* 83:40-7, 1998
71. Salmon SE, Crowley JJ, Balcerzak SP, et al: Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study. *J Clin Oncol* 16:890-6, 1998
72. Nagura E, Ichikawa A, Kamiya O, et al: A randomized study comparing VMCP and MMPP in the treatment of multiple myeloma. *Cancer Chemother Pharmacol* 39:279-85, 1997
73. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group. *Ann Intern Med* 124:212-22, 1996
74. Attal M, Harousseau JL, Stoppa AM, et al: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. *Intergroupe Francais du Myelome. The New England journal of medicine* 335:91-7, 1996
75. Westin J, Rodger S, Turesson I, et al: Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Cooperative Study Group. *Br J Haematol* 89:561-8, 1995
76. Cohen AM, Meytes D, Many A, et al: Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience. *Isr J Med Sci* 31:604-10, 1995
77. Gertz MA, Kalish LA, Kyle RA, et al: Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in

refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study. *Am J Clin Oncol* 18:475-80, 1995

78. Dalton WS, Crowley JJ, Salmon SS, et al: A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. *Cancer* 75:815-20, 1995

79. Keldsen N, Bjerrum OW, Dahl IM, et al: Multiple myeloma treated with mitoxantrone in combination with vincristine and prednisolone (NOP regimen) versus melphalan and prednisolone: a phase III study. Nordic Myeloma Study Group (NMSG). *Eur J Haematol* 51:80-5, 1993

80. Krishnan A, Pasquini MC, Logan B, et al: Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. *Lancet Oncol* 12:1195-203, 2011

81. Giaccone L, Sorasio R, Patriarca F, et al: Bortezomib after allografting in multiple myeloma: association between neurotoxicity and cyclosporine treatment. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation* 13:497-9, 2007

82. Femand JP, Ravaud P, Chevret S, et al: High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. *Blood* 92:3131-6, 1998

83. Palumbo A, Bringhen S, Caravita T, et al: Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. *Lancet* 367:825-31, 2006

84. Richardson PG, Sonneveld P, Schuster M, et al: Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. *Blood* 110:3557-3560, 2007

85. Garban F, Attal M, Michallet M, et al: Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. *Blood* 107:3474-3480, 2006

86. Kropff M, Baylon HG, Hillengass J, et al: Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. *Haematologica* 97:784-91, 2012

87. Krishnan A, Pasquini MC, Ewell M, et al: Tandem Autologous Hematopoietic Stem Cell Transplants (AuHCT) with or without Maintenance Therapy (auto-auto) Versus Single AuHCT Followed by HLA Matched Sibling Non- Myeloablative Allogeneic HCT (auto-allo) for Patients with Standard Risk (SR) Multiple Myeloma (MM): Results From the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial. *ASH Annual Meeting Abstracts* 116:41, 2010

88. Barlogie B, Tricot G, Anaissie E, et al: Thalidomide and hematopoietic-cell transplantation for multiple myeloma. *N Engl J Med* 354:1021-30, 2006

89. Durie BG, Harousseau JL, Miguel JS, et al: International uniform response criteria for multiple myeloma. *Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K* 20:1467-73, 2006

90. Rajkumar SV, Gahrton G, Bergsagel PL: Approach to the treatment of multiple myeloma: a clash of philosophies. *Blood* 118:3205-3211, 2011

Study	Year of publication	ARM A	ARM B	Phase of MM	PFS/TTP	PFS/TTP	PFS/TTP(ARM A-ARM B)	p	OS	OS	p value (OS)
					median ARM A	median ARM B		value( PFS)	(months) ARM A	(months)A RM B	
Facon et al.	2007	MPT	MP	New	27,5	17,8	9,7	<0.001	51,6	33,2	0,0006
J. F. San-Miguel et al.	2008	VMP	MP	New	24	16,6	7,4	<0.001	NR	NR	0.008
C. Hulin et al.	2009	MPT	MP	New	24,1	18,5	5,6	0,001	44	29,1	0.028
Zervas et al.	2007	TVAD-doxil	VAD-doxil	New	NR (at least 30 months)*	23	at least 7 months*	0,0013	NR	NR	0.037
P. Wijermans et al.	2010	MPT	MP	New	13	9	4	<0.05	40	31	0.05
Facon et al.	2007	MPT	MEL100	New	27,5	19,4	8,1	0,0002	51,6	38,3	0.027
Ludwig et al.	2009	MP	TD	New	20,7	16,7	4	0,1	49,4	41,5	0,024
N. Keldsen et al.	1993	MP	NOP	New	21	16	5	0,8	31	14	0.02
J. A. Child et al.	2003	Intensive therapy	Standard therapy	New	31,6	19,6	12	<0.001	54,1	42,3	0.04
M. Attal et al.	1996	ASCT	Conventional Dose CCT	New	27	18	9	0,01	60	37,4	0.03
A. Palumbo et al.	2004	MEL100 Auto	MP	New	28	15,6	12,4	1	58+	42.5	0,0005
Bruno et al./L. Giaccone et al.	2007	MEL200/200	Auto MEL 200/Allo TBI Control	Consolidation Maintenance	33	39	-6	0,07	63,6	NR	0,03
Spencer et al.	2009	Thal	group	Maintenance	30,5	18,3	12,2	<0.01	NR	NR	0.004
McCarthy, P. L. et al.	2012	Len	Placebo	Maintenance	39	21	18	<0.001	NR	NR	0.03
D. M. Weber et al.	2007	Len/Dex	Placebo/Dex	Relapse/Refractory	11,1	4,7	6,4	<0.001	29.6	20.2	<0.001
P. G. Richardson et al.	2007	Bortezomib update	High-Dex initial	Relapse/Refractory	6,2	3,5	2,7	NA	29.8	23.7	0.027
R. Z. Orlowski et al.	2007	PLD+Bortezomib	Bortezomib	Relapse/Refractory	9	6,5	2,5	0,0002	NR	NR	0.03
M. A. Dimopoulos et al.	2007	Len/Dex	Placebo/Dex	Relapse/Refractory	11,3	4,7	6,6	<0.001	NR	20.6	<0.001